Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)

NCT07260162 · tracked via the Priya Life Science France tracker

Sponsor

Institut Cancerologie de l'Ouest

Phase

Phase 1

Started

2027-01

Last updated

2026-06-08

Condition(s) studied

Bladder Cancer

Investigational drug(s) / intervention(s)

ATO-101™

ATO-101™: The study drug: \[211At\]At-Girentuximab (ATO-101™) is administered via intravesical instillation

Study summary

Non-Muscle-Invasive Bladder cancer (NMIBC) tumours often recur despite TransUrethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) intravesical instillations, and have no effective conservative treatment options. Alpha emitters like Astatine-211 (211At), due to their short path and short half-life, show promise for superficial targets such as NMIBC.

Carbonic anhydrase IX (CAIX), overexpressed in 70-90% of NMIBC cases but absent in healthy tissues, is an ideal target.

A clinical feasibility Positron emission tomography-computed tomography (PET/CT) imaging study (Pertinence, NCT04897763) was conducted at Institut de cancérologie Ouest (ICO) in six patients using Girentuximab labelled with Zirconium-89 (\[89Zr\]Zr-girentuximab). It demonstrated successful tracer targeting and no radioactive leakage beyond the bladder following intravesical instillation. The study also confirmed the absence of toxicity, contamination, or significant additional staff radiation exposure.

ATO-101™ (\[²¹¹At\]At-girentuximab) could enable localised tumour destruction while preserving the bladder in patients with BCG-unresponsive NMIBC. The ongoing First In Human (FIH) study evaluate the safety of ATO-101™ in patients with BCG-unresponsive NMIBC.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Performance Status (PS): 0 or 1. * Patient experiencing relapse following standard treatment (BCG therapy with or without Mitomycin), before radical surgery which is being considered as a therapeutic option. * Clinical evidence of NMIBC based on cystoscopy and proven histologically of papillary tumours. * Histologically confirmed bladder cancer patients relapsing without muscle invasion. * Negative serum/urine pregnancy test prior to ATO-101™ administration for female patient of childbearing potential. * Consent to use a contraception method for at least 3 months after administration of ATO-101™. * Adequate organ function confirmed by laboratory tests results allowing for safe administration of ATO-101™. Exclusion Criteria: * Patient with urinary incontinence. * Patient treated with anticoagulant or platelet antiaggregant therapies. * Symptoms of urine infection. * Patient with urethral stenosis. * Patient with valvular heart disease. * No history of congestive heart failure. * Known hypersensitivity to Girentuximab. * Exposure to any experimental diagnostic or therapeutic drug within 30 days prior the date of planned administration of ATO-101™. * Serious non-malignant disease that may interfere with the objectives of the study or with the safety or compliance of the patient as judged by the investigator. * Concomitant cancer in the past 5 years except cutaneous cancers (except melanoma) and in situ carcinoma in past 3 years. * Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), immunotherapy within 21 days of ATO-101™ administration. * Pregnant or likely to be pregnant or nursing patient.

Primary outcome measure(s)

To determine the Maximum Tolerated Dose (MTD) of ATO-101™. — 15 days
The primary endpoint is the occurrence of dose-limiting toxicities (DLTs) during the DLT observation period.
To determine the Recommended Dose for Expansion (RDE) of ATO-101™. — 15 days
The primary endpoint is the occurrence of dose-limiting toxicities (DLTs) during the DLT observation period.

Trial sites (1)

Facility	City	Region	Status
Institut de Cancérologie de l'Ouest	Saint-Herblain	Loire Atlantique

More Institut Cancerologie de l'Ouest trials in France

To Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer Recruiting

Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Aromatase Inhibitor-induced Arthralgia (AIA) Starting soon

OP2C : Prialt® Observatory in Clinical Practice Recruiting

Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease Starting soon

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer Active, not recruiting

Other trials for the same condition

Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers Recruiting

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) Recruiting

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy Active, not recruiting

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients Active, not recruiting

Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07260162 on ClinicalTrials.gov ↗ ← All trials in France